Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04691661
Recruitment Status : Not yet recruiting
First Posted : December 31, 2020
Last Update Posted : August 25, 2021
Sponsor:
Information provided by (Responsible Party):
Il-Yang Pharm. Co., Ltd.

Brief Summary:
This is a safety, tolerability, pharmacokinetic and efficacy study in subjects with Parkinson's disease

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: Radotinib HCl 50 mg Drug: Placebo Phase 2

Detailed Description:

This study is will be conducting to determine if Radotinib is safe and can be tolerated by patients with Parkinson's disease (PD) and to learn if Radotinib can be potential therapeutic agents for the treatment of PD.

Radotinib has been approved by Ministry of Food & Drug Safety of Korea to treat Chronic Myeloid Leukemia (CML) but it has not been approved for PD.

In nonclinical efficacy study, therapeutic effect of Radotinib HCl, c-Abl inhibitor, which exhibits improved pharmacokinetic properties and BBB penetration compared to nilotinib and other c-Abl inhibitors, was tested in a preclinical α-synuclein preformed fibrils (PFF) model of sporadic PD. As a result, the treatment of Radotinib HCl protects the α-synuclein PFFs-induced neuronal toxicity, reduces the PFFs-induced LB/LN-like pathology, and inhibits the PFFs-induced c-Abl activation in neurons. In vivo studies demonstrate that administration of Radotinib HCl prevents dopamine neuron loss and behavioral deficits following α-synuclein PFFs-induced toxicity. Taken together, these findings indicate that Radotinib HCl has beneficial neuroprotective effects in PD and provides strong evidence that selective and brain permeable c-Abl inhibitors can be potential therapeutic agents for the treatment of PD.

These data are very compelling to evaluate the effects of Radotinib in a phase II, randomized, double-blind, placebo-controlled trial in patients with PD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease
Estimated Study Start Date : August 24, 2021
Estimated Primary Completion Date : January 29, 2022
Estimated Study Completion Date : April 13, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo: Dose escalation
Forty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.
Drug: Placebo
Placebo

Experimental: Radotinib HCl: Dose escalation

Forty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.

The inclusion of subjects in the next dose level will be decided by the sponsor in consultation with a Data Monitoring Committee (DMC).

Drug: Radotinib HCl 50 mg
Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
Other Names:
  • Radotinib
  • IY5511




Primary Outcome Measures :
  1. Evaluation of safety parameters: Adverse Events [ Time Frame: 12 months after dose administration ]
    Incidence and severity of treatment emergent AEs


Secondary Outcome Measures :
  1. Pharmacokinetics assessments of Radotinib HCl: Cmax [ Time Frame: 14 days after dose administration ]
    The maximum (peak) observed drug concentration after dose administration

  2. Pharmacokinetics assessments of Radotinib HCl: Tmax [ Time Frame: 14 days after dose administration ]
    The time to reach maximum (peak) drug concentration after dose administration

  3. Pharmacokinetics assessments of Radotinib HCl: Ctrough [ Time Frame: 14 days after dose administration ]
    Trough plasma concentration (measured concentration at the end of a dosing interval at steady state)

  4. Pharmacokinetics assessments of Radotinib HCl: AUCt [ Time Frame: 14 days after dose administration ]
    Area under the plasma concentration-time curve from time zero to time t

  5. Pharmacokinetics assessments of Radotinib HCl: AUCinf [ Time Frame: 14 days after dose administration ]
    Area under plasma concentration-time curve from time 0 to infinity

  6. Pharmacokinetics assessments of Radotinib HCl: AUC0-24h [ Time Frame: 14 days after dose administration ]
    Area under the plasma concentration-time curve over the last 24-h dosing interval

  7. Pharmacokinetics assessments of Radotinib HCl: t1/2 [ Time Frame: 14 days after dose administration ]
    Elimination half-life of Radotinib after dose administration

  8. Pharmacokinetics assessments of Radotinib HCl: Vd/F [ Time Frame: 14 days after dose administration ]
    Apparent volume of distribution after non-intravenous administration

  9. Pharmacokinetics assessments of Radotinib HCl: CL/F [ Time Frame: 14 days after dose administration ]
    Apparent total clearance of the drug from plasma after oral administration

  10. Change from Baseline in the sum of MDS-UPDRS Parts I, II and III [ Time Frame: 6 months ]

    The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society.

    The MDS-UPDRS has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living, Part III (motor examination) and Part IV (motor complications). Only Parts I, II and III will be completed in this study.

    MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale has a 0-4 rating, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Higher MDS-UPDRS scores reflect worse tremor/motor function. Larger differences will infer greater effect size for the intervention. Score drops over time imply improvement in tremor/motor function.


  11. Time from baseline to initiation of dopamine-replacement medication. [ Time Frame: 6 months ]
    Time from baseline to initiation of dopamine replacement therapy following randomization

  12. Change in health related quality of life as measured by a quality of life questionnaire (PDQ-39) [ Time Frame: 12 months ]
    The Parkinson's Disease Questionnaire (PDQ-39) is a 39-item quality of life questionnaire for patients with Parkinson's Disease (PD) that evaluates the 8 dimensions of mobility, activities of daily living, emotional well-being, stigma, social support, cognition, and communication. The PDQ-39 Single Index (SI) score is the weighted addition of scores on all 8 dimension and ranges from 0 (no disease impact) to 100 (severe disease impact).

  13. Subject's clinical global impression of change. [ Time Frame: 12 months ]
    The CGI Scale of Global Clinical Impressions (see Appendix VI) allows an overall assessment of the subject's condition. The CGI addresses the majority of mental disorders. In its first item, rated from 1 to 7 (the rating 1 corresponding to the normal state), it allows a good overall measurement of the subject's condition. The 2nd item proposes to the Investigator to evaluate the overall improvement of the subject compared to his/her condition at the admission to the research. As before, this item has 7 quantified degrees (from 1 = "very strongly improved" to 7 = "very strongly aggravated").


Other Outcome Measures:
  1. Brain DaT SPECT to measure dopamine neurons and nerve terminals [ Time Frame: 12 months ]
    DaTscan is a specific type of single-photon emission computed tomography (SPECT) imaging technique that helps visualize dopamine transporter in the brain

  2. Concentration of α-synuclein in CSF [ Time Frame: 6 months ]
    Quantification of α-synuclein concentration in CSF

  3. Concentration of Tau and phospho-Tau (p-181) in CSF [ Time Frame: 6 months ]
    Quantification of Tau and phospho-Tau (p-181) concentration in CSF

  4. Concentration of β-amyloid peptide 1-42 in CSF [ Time Frame: 6 months ]
    Quantification of β-amyloid peptide 1-42 concentration in CSF

  5. Concentration of NF-L in the serum [ Time Frame: 6 months ]
    Quantification of NF-L concentration in CSF

  6. Concentration of Radotinib HCl in the CSF and plasma [ Time Frame: 6 months ]
    Quantification of Radotinib HCl concentration in CSF



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and Female from 40 to 80 years old;
  2. Diagnosed with "Clinically Probable Parkinson's Disease" according to the MDS clinical diagnostic criteria, with documented onset of symptoms per treating physician's records within three years of the screening visit;
  3. Positive DAT-scan (e.g. a striatal dopamine transporter deficit on dopamine transporter imaging by DaT-SPECT, characterized by crescent-shaped areas of asymmetrical aspect, or of symmetrical aspect but of uneven intensity, between the right and the left brain hemisphere) confirmed by local reading;
  4. Hoehn & Yahr stage ≤ 2.5;
  5. Without previous symptomatic treatment for PD disease and with current clinical state not requiring started dopaminergic therapy within 6 months from Baseline;
  6. Absence of a parkinsonian syndrome and other neurovascular comorbidities, confirmed by MRI
  7. Female subjects must be not of childbearing potential, e.g., documented evidence that they are surgically sterile (e.g., hysterectomy, partial hysterectomy, bilateral oophorectomy, bilateral tubal ligation), or post-menopausal (at least 12 months since last menses) and with negative pregnancy test at screening;
  8. Covered by Health Insurance System;
  9. Able to understand and to sign the informed consent prior to screening;
  10. Blood Pressure (BP) and Heart Rate (HR) considered NCS by Investigator;
  11. Electrocardiogram (ECG) recording on a 12-lead ECG considered NCS by Investigator;
  12. Laboratory parameters within the normal range of the laboratory. Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator.

Exclusion Criteria:

  1. Atypical Parkinsonism or drug-induced Parkinsonism;
  2. Current, or within 60 days of screening, use of any prescription, investigational, or over the counter medication for the symptomatic treatment of PD or to slow the progression of PD.
  3. Prior use of dopaminergic therapy (e.g., levodopa, dopamine agonist, amantadine, rasagiline) for 30 or more days any time in the past;
  4. Cognitive impairment (MMSE ≤ 24);
  5. Active psychiatric disorder (mood disorders, hallucinations or delirium with strong functional impact and not controlled by medication or which happened during the last 3 months before inclusion);
  6. Severe or uncontrolled chronic disease;
  7. Significant medical history of congenital or acquired bleeding disorders;
  8. Treatment by Deep Brain Stimulation or continuous infusion of apomorphin/dopa gel;
  9. Any below impaired cardiac function:

    • LVEF <45% or < lower bound of normal limit of study site (whichever higher), confirmed by echocardiogram (if the subject has already carried out this examination during the last month before inclusion, he/she will be exempted from retaking this examination, but he/she will have to present the echocardiogram as well as the cardiologist's report. If not, this exam should be performed during the screening period)
    • Subjects who cannot have QT intervals measured according to ECG
    • Complete left bundle branch block
    • Subjects with cardiac pacemakers
    • Subjects with congenital long QT syndrome or the family history of known long QT syndrome
    • History of, or presence of symptomatic ventricular or atrial tachyarrhythmias
    • Clinically significant resting bradycardia (< 50 bpm).
    • Mean QTcF >450msec following three consecutive ECG tests at baseline: Screening test will be performed again for QTcF after the adjustment of electrolyte if QTcF >450msec and the electrolyte is not within the normal range
    • Medical history of clinically confirmed myocardial infarction
    • Medical history of unstable angina (within last 12 months)
    • Other clinically significant cardiac disease (e.g. congestive heart failure, or uncontrolled hypertension)
  10. Participation in other investigational drug trials within 30 days prior to Screening;
  11. Any concomitant medication or medication excluded that could put subject at risk, or interfere with study evaluations;
  12. Subjects currently receiving treatment with a strong CYP3A4 inhibitors (e.g. erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) or strong CYP3A4 inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbitol, St. John's Wort) or therapeutic Cumarin derivatives (e.g. warfarin, acenocoumarol, phenprocoumon) and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs
  13. Subjects who are currently receiving treatment with a medication that has the potential to extend QT intervals and can neither stop the administration of the drugs before the start of the IP administration nor switch to other drugs (list of medications that have the potential to prolong QT interval is provided in the Appendix II) If subjects need to start such drug treatments during the study, this will be discussed with the sponsor, IL-YANG PHARM. Co., Ltd.
  14. Subjects who are currently receiving treatment with P-gp inducers (e.g. (Ritonavir, Saquinavir, Nelfinavir, Indinavir, Amprenavir, Tipranavir…), Apalutamide, Estrone, Estriol, Trazodone, Vincristine, Tamoxifen, Doxorubicin, Carbamazepine, Oxcarbazepine, Fosphenytoin, Lorlatinib, Phenobarbital, Phenytoin, Propofol, beclomethasone, Dexamethasone, Prednisone, Hydrocortisone, Diclofenac, Rifampicin, Reserpine, Nifedipine, Digoxine, Amiodarone, Spironolactone, Levothyroxine, Tacrolimus, Sirolimus, St. John's Wort (herbal ingredient)) and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs;
  15. Gastrointestinal disorder or gastrointestinal disease that may result in a significant change in the absorption of the investigational product;
  16. Medical history of acute or chronic pancreatitis within the past one year;
  17. Acute or chronic liver, pancreas, or severe kidney disease that are not associated with the disease;
  18. Subjects known seropositive to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, or cirrhosis. Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA < 500 IU/mL or site specific local lab normal range lower limit assessed by investigator), and cured hepatitis C subjects can be enrolled;
  19. Men subjects who are unwilling to use and appropriate method of contraception during the study;
  20. Subjects who have hypersensitivity to active ingredient or any of the excipients of this investigational product;
  21. Any medical condition that might interfere with the protocol except those defined in Section 5.3 of the study protocol;
  22. Subject unable to attend scheduled visits or to comply to the protocol;
  23. Subject under legal guardianship or judicial protection;
  24. Subject in the exclusion period of another protocol;
  25. No possibility of contact in case of emergency.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04691661


Contacts
Layout table for location contacts
Contact: IL-YANG CR +82.2.570.3700 nykim@ilyanga.co.kr

Locations
Layout table for location information
France
CHRU de Lille - Hôpital Roger Salengro
Lille, France
Contact: Luc DEFEBVRE         
CHU Limoges
Limoges, France
CHU de Lyon HCL
Lyon, France
Contact: Stephane THOBOIS         
Hôpital Nantes-Hotel Dieu
Nantes, France
Contact: Damier Philippe         
Hôpital Pitié-Salpêtrière
Paris, France
Contact: LOUISE LAURE MARIANI         
Chu La Miletrie
Poitiers, France
Contact: Isabelle BEBATRU         
CHU de Rouen
Rouen, France
Contact: David MALTETE         
Sponsors and Collaborators
Il-Yang Pharm. Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Philippe DAMIER, Pr. CHU Nantes - Hôpital Nord Guillaume et René Laennec
Layout table for additonal information
Responsible Party: Il-Yang Pharm. Co., Ltd.
ClinicalTrials.gov Identifier: NCT04691661    
Other Study ID Numbers: RT51EP1902
First Posted: December 31, 2020    Key Record Dates
Last Update Posted: August 25, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases